CO5271711A1 - Una composicion que comprende sildenafil o 3-etil-5-[5-(4-etil-piperazina-1-sulfonil)-2-propoxi-fenil]-2-piridinh-2-ilmetil-2.6-dihidropirazolo[4,3-d]pirimidin-7-ona y gabapentina o pregabalina para el tratamiento de la neuropatia diabetica - Google Patents
Una composicion que comprende sildenafil o 3-etil-5-[5-(4-etil-piperazina-1-sulfonil)-2-propoxi-fenil]-2-piridinh-2-ilmetil-2.6-dihidropirazolo[4,3-d]pirimidin-7-ona y gabapentina o pregabalina para el tratamiento de la neuropatia diabeticaInfo
- Publication number
- CO5271711A1 CO5271711A1 CO00080163A CO00080163A CO5271711A1 CO 5271711 A1 CO5271711 A1 CO 5271711A1 CO 00080163 A CO00080163 A CO 00080163A CO 00080163 A CO00080163 A CO 00080163A CO 5271711 A1 CO5271711 A1 CO 5271711A1
- Authority
- CO
- Colombia
- Prior art keywords
- etil
- treatment
- piridinh
- gabapentina
- dihydropirazol
- Prior art date
Links
- 208000032131 Diabetic Neuropathies Diseases 0.000 title abstract 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 title 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 title 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title 1
- 229960003310 sildenafil Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 2
- GDSBGVNDBUSBRO-UHFFFAOYSA-N 2-phenylpurin-6-one Chemical class N1=C2N=CN=C2C(=O)N=C1C1=CC=CC=C1 GDSBGVNDBUSBRO-UHFFFAOYSA-N 0.000 abstract 1
- SNDXSHHDQKGQHR-UHFFFAOYSA-N 2-pyridin-3-yl-4a,5-dihydro-1h-imidazo[5,1-f][1,2,4]triazin-4-one Chemical group N=1N2C=NCC2C(=O)NC=1C1=CC=CN=C1 SNDXSHHDQKGQHR-UHFFFAOYSA-N 0.000 abstract 1
- NDKDAFIYBRIRDE-UHFFFAOYSA-N 2-pyridin-3-ylpurin-6-one Chemical class N1=C2N=CN=C2C(=O)N=C1C1=CC=CN=C1 NDKDAFIYBRIRDE-UHFFFAOYSA-N 0.000 abstract 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 abstract 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 abstract 1
- 101150098694 PDE5A gene Proteins 0.000 abstract 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Un procedimiento para tratar a un paciente que sufre neuropatía, que comprende tratar a dicho paciente con una cantidad eficaz de un inhibidor de la GMPc PDE5, con la condición de que el inhibidor no sea: 5-(3-piridil)pirazolo [4,3-d]pirimidin-7-ona sustituida, 2-(3-piridil)-4a, 5-dihidroimidazo[5,1-f][1,2,4]triazin-4(3H)-ona sustituida, o 2-fenilpurin-6-ona sustituida o 2 -(3-piridil)purin-6-ona sustituida para el tratamiento de la neuropatía diabética periférica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9924958.3A GB9924958D0 (en) | 1999-10-21 | 1999-10-21 | Treatment of neuropathy |
GB0021520A GB0021520D0 (en) | 2000-09-01 | 2000-09-01 | Treatment of neuropathy |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5271711A1 true CO5271711A1 (es) | 2003-04-30 |
Family
ID=26244947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00080163A CO5271711A1 (es) | 1999-10-21 | 2000-10-20 | Una composicion que comprende sildenafil o 3-etil-5-[5-(4-etil-piperazina-1-sulfonil)-2-propoxi-fenil]-2-piridinh-2-ilmetil-2.6-dihidropirazolo[4,3-d]pirimidin-7-ona y gabapentina o pregabalina para el tratamiento de la neuropatia diabetica |
Country Status (16)
Country | Link |
---|---|
US (2) | US20030162782A1 (es) |
EP (2) | EP1129706A3 (es) |
JP (2) | JP2001122803A (es) |
KR (1) | KR20010051181A (es) |
AT (1) | ATE380049T1 (es) |
AU (1) | AU781550B2 (es) |
CA (1) | CA2323839C (es) |
CO (1) | CO5271711A1 (es) |
CY (1) | CY1107285T1 (es) |
DE (1) | DE60037347T2 (es) |
DK (1) | DK1440709T3 (es) |
ES (1) | ES2295726T3 (es) |
HU (1) | HUP0004120A3 (es) |
IL (2) | IL139073A0 (es) |
PE (1) | PE20010754A1 (es) |
PT (1) | PT1440709E (es) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001257146B2 (en) * | 2000-04-19 | 2006-11-30 | Johns Hopkins University | Methods for prevention and treatment of gastrointestinal disorders |
FR2809623B1 (fr) * | 2000-06-05 | 2003-09-05 | Sanjuan Benito Arranz | Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : du sildenafil (ou de ses derives) |
DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
US20030211040A1 (en) | 2001-08-31 | 2003-11-13 | Paul Greengard | Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain |
GB0129274D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Novel kit |
US20050143388A1 (en) * | 2002-01-04 | 2005-06-30 | Michael Chopp | Nitric oxide donors for treatment of disease and injury |
US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
GB0219024D0 (en) * | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
US7659305B2 (en) | 2002-10-31 | 2010-02-09 | Pfizer Inc. | Therapeutic proline derivatives |
CA2509605C (en) * | 2002-12-13 | 2010-10-05 | Warner-Lambert Company Llc | Alpha-2-delta ligand to treat lower urinary tract symptoms |
EP2308828A3 (en) | 2003-04-23 | 2013-05-22 | Japan Tobacco Inc. | CaSR antagonist |
DE10325813B4 (de) | 2003-06-06 | 2007-12-20 | Universitätsklinikum Freiburg | Prophylaxe und/oder Therapie bei der portalen Hypertonie |
ATE445402T1 (de) | 2004-03-05 | 2009-10-15 | Nycomed Gmbh | Neue verwendung von pde5-hemmern |
CN103467471A (zh) | 2005-06-06 | 2013-12-25 | 武田药品工业株式会社 | 有机化合物 |
US20080194592A1 (en) * | 2005-08-23 | 2008-08-14 | Intra-Cellular Therapies, Inc. | Organic Compounds |
JP5453086B2 (ja) * | 2006-06-06 | 2014-03-26 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
WO2008063505A1 (en) * | 2006-11-13 | 2008-05-29 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2008070095A1 (en) | 2006-12-05 | 2008-06-12 | Intra-Cellular Therapies, Inc. | Novel uses |
US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
WO2008131256A1 (en) * | 2007-04-19 | 2008-10-30 | Trinity Laboratories Inc. | Improved treatments for premature ejaculation in humans |
BRPI0814294A2 (pt) | 2007-07-19 | 2015-02-03 | Metabolex Inc | Agonistas de receptor heterocíclico ligado a n para o tratamento do diabetes e de desordens metabólicas. |
KR101227738B1 (ko) * | 2007-12-06 | 2013-01-29 | 다케다 야쿠힌 고교 가부시키가이샤 | 유기 화합물 |
US8846693B2 (en) * | 2007-12-06 | 2014-09-30 | Intra-Cellular Therapies, Inc. | Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones |
GEP20146046B (en) | 2008-12-06 | 2014-02-25 | Intracellular Therapies Inc | Organic compounds |
EP2367429B1 (en) | 2008-12-06 | 2017-06-07 | Intra-Cellular Therapies, Inc. | Organic compounds |
MA32940B1 (fr) | 2008-12-06 | 2012-01-02 | Intra Cellular Therapies Inc | Composes organiques |
EP2367428B1 (en) | 2008-12-06 | 2016-04-06 | Intra-Cellular Therapies, Inc. | Organic compounds |
MX2011005937A (es) | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
MX2011005936A (es) * | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
WO2010098839A1 (en) | 2009-02-25 | 2010-09-02 | Intra-Cellular Therapies, Inc. | Pde 1 inhibitors for ophthalmic disorders |
JP2012526810A (ja) | 2009-05-13 | 2012-11-01 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
EP2461673A4 (en) | 2009-08-05 | 2013-08-07 | Intra Cellular Therapies Inc | NEW REGULATOR PROTEINS AND HEMMER |
WO2011041154A1 (en) | 2009-10-01 | 2011-04-07 | Metabolex, Inc. | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
WO2011143607A1 (en) * | 2010-05-14 | 2011-11-17 | The Regents Of The University Of California | Modulation of bioactive epoxy-fatty acid levels by phosphodiesterase inhibitors |
EP2590657A4 (en) | 2010-05-31 | 2014-02-12 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS |
JP5879336B2 (ja) | 2010-05-31 | 2016-03-08 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
WO2011153138A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
US20130143894A1 (en) * | 2010-06-07 | 2013-06-06 | vadel Pharma Inc. | Oral spray formulations ad methods for administration of sildenafil |
CN109674753A (zh) | 2010-06-23 | 2019-04-26 | 希玛贝治疗股份有限公司 | 固态分散体 |
WO2012171016A1 (en) | 2011-06-10 | 2012-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
CN102276511A (zh) * | 2011-06-20 | 2011-12-14 | 兰州博实生化科技有限责任公司 | 1-叔丁氧羰基-3-碘氮杂环丁烷的合成方法 |
US8449565B2 (en) | 2011-07-21 | 2013-05-28 | Francis Duhay | Approaches to venous occlusion for embolus management |
WO2014127331A1 (en) | 2013-02-17 | 2014-08-21 | Intra-Cellular Therapies, Inc. | Novel uses |
MX2015013042A (es) | 2013-03-15 | 2016-05-05 | Intra Cellular Therapies Inc | Compuestos organicos. |
EP3479825B1 (en) | 2013-03-15 | 2021-02-17 | Intra-Cellular Therapies, Inc. | Pde1 inhibitors for use in the treatment and/or prevention of cns or pns diseases or disorders |
RU2549459C2 (ru) * | 2013-08-20 | 2015-04-27 | Константин Александрович Корейба | Способ лечения нейропатических трофических язв при синдроме диабетической стопы |
US9849132B2 (en) | 2014-01-08 | 2017-12-26 | Intra-Cellular Therapies, Inc. | Products and pharmaceutical compositions |
ES2732442T3 (es) | 2014-06-20 | 2019-11-22 | Intra Cellular Therapies Inc | Compuestos orgánicos |
US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
JP6591530B2 (ja) | 2014-08-07 | 2019-10-16 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
US10150774B2 (en) | 2014-09-17 | 2018-12-11 | Intra-Cellular Therapies, Inc. | Compounds and methods |
KR102557603B1 (ko) | 2014-12-06 | 2023-07-19 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
US10105349B2 (en) | 2014-12-06 | 2018-10-23 | Intra-Cellular Therapies, Inc. | Organic compounds |
US10813894B2 (en) | 2015-02-20 | 2020-10-27 | The Regents Of The University Of California | Methods of inhibiting pain |
WO2017172795A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
CA3032432A1 (en) | 2016-08-03 | 2018-02-08 | Charles A. Mcwherter | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
AU2017322427B2 (en) | 2016-09-09 | 2021-12-23 | Incyte Corporation | Pyrazolopyridine derivatives as HPK1 modulators and uses thereof for the treatment of cancer |
TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
EP3509589B1 (en) | 2016-09-12 | 2021-11-17 | Intra-Cellular Therapies, Inc. | Novel uses |
WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
WO2019051199A1 (en) | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS |
MX2017016930A (es) * | 2017-12-19 | 2019-06-20 | Malesil Research & Tech Llc | Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico. |
JP7401442B2 (ja) | 2018-01-31 | 2023-12-19 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
KR20200133747A (ko) | 2018-02-20 | 2020-11-30 | 인사이트 코포레이션 | 암을 치료하기 위한 hpk1 억제제로서의 n-(페닐)-2-(페닐)피리미딘-4-카복스아미드 유도체 및 관련 화합물 |
US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
WO2020068729A1 (en) | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
KR20220059480A (ko) | 2019-08-06 | 2022-05-10 | 인사이트 코포레이션 | 고체 형태의 hpk1 억제제 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
AU722514B2 (en) * | 1995-12-28 | 2000-08-03 | Fujisawa Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
USRE41920E1 (en) * | 1996-07-24 | 2010-11-09 | Warner-Lambert Company Llc | Isobutylgaba and its derivatives for the treatment of pain |
US6127418A (en) * | 1997-08-20 | 2000-10-03 | Warner-Lambert Company | GABA analogs to prevent and treat gastrointestinal damage |
AU748352B2 (en) * | 1998-04-20 | 2002-06-06 | Pfizer Inc. | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction |
US6331171B1 (en) * | 1998-06-04 | 2001-12-18 | Alcon Laboratories, Inc. | Tip for a liquefracture handpiece |
WO2000024745A1 (en) * | 1998-10-23 | 2000-05-04 | Pfizer Limited | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
GB9823101D0 (en) * | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
GB9823103D0 (en) * | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
US6453237B1 (en) * | 1999-04-23 | 2002-09-17 | Global Locate, Inc. | Method and apparatus for locating and providing services to mobile devices |
US6411892B1 (en) * | 2000-07-13 | 2002-06-25 | Global Locate, Inc. | Method and apparatus for locating mobile receivers using a wide area reference network for propagating ephemeris |
IL137429A0 (en) * | 1999-07-28 | 2001-07-24 | Pfizer Prod Inc | Methods and compsitions for treating diseases and conditions of the eye |
AU779761C (en) * | 1999-10-12 | 2005-09-22 | Lilly Icos Llc | Medicament for treatment of neuropathies |
US7196660B2 (en) * | 2000-11-17 | 2007-03-27 | Global Locate, Inc | Method and system for determining time in a satellite positioning system |
US6560534B2 (en) * | 2001-06-06 | 2003-05-06 | Global Locate, Inc. | Method and apparatus for distributing satellite tracking information |
-
2000
- 2000-10-16 IL IL13907300A patent/IL139073A0/xx unknown
- 2000-10-16 IL IL152925A patent/IL152925A/en not_active IP Right Cessation
- 2000-10-17 PT PT04010436T patent/PT1440709E/pt unknown
- 2000-10-17 DK DK04010436T patent/DK1440709T3/da active
- 2000-10-17 EP EP00309129A patent/EP1129706A3/en not_active Withdrawn
- 2000-10-17 DE DE60037347T patent/DE60037347T2/de not_active Expired - Fee Related
- 2000-10-17 ES ES04010436T patent/ES2295726T3/es not_active Expired - Lifetime
- 2000-10-17 AT AT04010436T patent/ATE380049T1/de not_active IP Right Cessation
- 2000-10-17 EP EP04010436A patent/EP1440709B1/en not_active Expired - Lifetime
- 2000-10-19 CA CA002323839A patent/CA2323839C/en not_active Expired - Fee Related
- 2000-10-20 AU AU66650/00A patent/AU781550B2/en not_active Withdrawn - After Issue
- 2000-10-20 PE PE2000001133A patent/PE20010754A1/es not_active Application Discontinuation
- 2000-10-20 CO CO00080163A patent/CO5271711A1/es not_active Application Discontinuation
- 2000-10-20 HU HU0004120A patent/HUP0004120A3/hu unknown
- 2000-10-21 KR KR1020000062129A patent/KR20010051181A/ko not_active Application Discontinuation
- 2000-10-23 JP JP2000322510A patent/JP2001122803A/ja active Pending
-
2002
- 2002-07-26 US US10/206,615 patent/US20030162782A1/en not_active Abandoned
- 2002-10-10 JP JP2002297617A patent/JP2003119131A/ja active Pending
-
2003
- 2003-12-10 US US10/731,905 patent/US20040122010A1/en not_active Abandoned
-
2008
- 2008-02-18 CY CY20081100193T patent/CY1107285T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
KR20010051181A (ko) | 2001-06-25 |
CA2323839A1 (en) | 2001-04-21 |
EP1440709A3 (en) | 2004-12-08 |
AU781550B2 (en) | 2005-05-26 |
PE20010754A1 (es) | 2001-07-18 |
EP1440709A2 (en) | 2004-07-28 |
EP1129706A3 (en) | 2002-01-02 |
PT1440709E (pt) | 2008-02-06 |
HUP0004120A3 (en) | 2003-11-28 |
CA2323839C (en) | 2008-03-18 |
AU6665000A (en) | 2001-04-26 |
EP1129706A2 (en) | 2001-09-05 |
US20040122010A1 (en) | 2004-06-24 |
DE60037347T2 (de) | 2008-11-27 |
DE60037347D1 (de) | 2008-01-17 |
HUP0004120A2 (hu) | 2002-11-28 |
ES2295726T3 (es) | 2008-04-16 |
US20030162782A1 (en) | 2003-08-28 |
CY1107285T1 (el) | 2012-11-21 |
JP2001122803A (ja) | 2001-05-08 |
IL152925A (en) | 2010-04-15 |
IL139073A0 (en) | 2001-11-25 |
ATE380049T1 (de) | 2007-12-15 |
HU0004120D0 (es) | 2001-01-29 |
EP1440709B1 (en) | 2007-12-05 |
DK1440709T3 (da) | 2008-03-17 |
JP2003119131A (ja) | 2003-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5271711A1 (es) | Una composicion que comprende sildenafil o 3-etil-5-[5-(4-etil-piperazina-1-sulfonil)-2-propoxi-fenil]-2-piridinh-2-ilmetil-2.6-dihidropirazolo[4,3-d]pirimidin-7-ona y gabapentina o pregabalina para el tratamiento de la neuropatia diabetica | |
MY140557A (en) | Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders | |
ATE469903T1 (de) | Zur behandlung von krebserkrankungen geeignete pyrazolopyrimidine | |
ATE297208T1 (de) | Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit | |
HK1008222A1 (en) | Pyrrolopyrimidines and processes for the preparation thereof | |
HRP20070534T3 (en) | Phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor | |
NZ517758A (en) | Pyrazolopyrimidines useful as therapeutic agents | |
TW200420564A (en) | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
TR199800960A3 (tr) | Neoplastik lezyonlari önleyen bilesimlerin belirlenmesi için yöntem. | |
DK1014990T3 (da) | Antitumorkombination af 3 amino-1,2,4 benzotriazin-1,4 dioxid/paclitaxel/platin | |
ES2196824T3 (es) | Derivado de triazolo-piridazina sustituido y composiciones farmaceuticas fabricadas con el mismo. | |
AU1683901A (en) | Use of pdt to inhibit intimal hyperplasia | |
PT1140044E (pt) | Inibidores de pde 5 cgmp para inalacao no tratamento de disfuncao sexual | |
ES2194104T3 (es) | Uso de selegilina para el tratamiento de la perdida de audicion en mamiferos. | |
ES2140648T3 (es) | Compuestos de 5-alcoxi(1,2,4)triazol(1,5-c)pirimidin-2(3h)-tiona y su uso en la preparacion de 2,2'-ditiobis(5-alcoxi(1,2,4)triazol(1,5-c)pirimidina) y 2-clorosulfonil-5-alcoxi(1,2,4)triazol(1,5-c)pirimidina. | |
ES2183949T3 (es) | Combinacion de productos activos. | |
MY138201A (en) | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
DK14489A (da) | Anvendelse af en imidazobenzodiazepin til fremstilling af midler til behandling af psykotiske sygdomme. | |
WO1992007564A3 (en) | Method of treating demyelinating disease | |
ATE296631T1 (de) | Verwendung von pde5 inhibitoren zur behandlung vorzeitiger ejakulation | |
TH148526B (th) | ไพราโซโลไพริมิดีนชนิดใหม่ (Novel pyrazolopyrimidines) ล่าสุดในฐานะตัวยับยั้งไซคลินดีเพนเดนท์คิเนส (Cyclin dependent kinase inhibitors) | |
ES2025787T3 (es) | Procedimiento de tratamiento de madera. | |
ES2092685T3 (es) | Uso de atipamezol para el tratamiento de impotencia sexual masculina. | |
MY138266A (en) | Treatment of neuropathy | |
NZ330616A (en) | Potentiation of temozolomide toxicity in human cancer cells using inhibitors of ATase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted | ||
FD | Application lapsed |